GlaxoSmithKline | GSK - Current Liabilities


GlaxoSmithKline reported GBP21.53B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Alcon AG USD 3B 45M Mar/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amgen USD 24.96B 534M Mar/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 33.46B 875M Mar/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Fresenius EUR 8.38B 1.18B Dec/2025
Fresenius Medical Care EUR 6.73B 484.42M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.35B 307M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Orion EUR 454.5M 344.1M Jun/2026
Pfizer USD 34.35B 2.64B Mar/2026
Philips EUR 7.42B 8M Jun/2026
Recordati EUR 1.4B 30.88M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Smith & Nephew USD 1.54B 236M Dec/2025
UCB EUR 4.4B 470M Dec/2025